Top Markets
#1 QuantixAI QuantixAI +63.61%
#2 Versatize Coin Versatize Coin +40.00%
#3 GEKKO GEKKO +36.52%
#4 Pons Pons +30.26%
#5 UnifAI Network UnifAI Network +30.11%
#6 MowCat MowCat +29.89%
#7 Prom Prom +28.67%
#8 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +26.23%
#9 MarsCoin MarsCoin +25.18%
#10 Kinesis Silver Kinesis Silver +23.42%
Coin of the day
QuantixAI QuantixAI
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Vaxart, Inc. Vaxart, Inc.

Vaxart, Inc.

VXRT
Rang in aandelen #20725
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Aandeelprijs
$0.5194
Marktkapitalisatie
$125.72M
Verandering (1 dag)
-0.12%
Verandering (1 jaar)
48.40%
Land
US
Handel Vaxart, Inc. (VXRT)

Categorie

Healthcare
Winst voor Vaxart, Inc. (VXRT)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Vaxart, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Vaxart, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH